Sinocare 관리

관리 기준 확인 4/4

Sinocare CEO는 Shao Bo Li, Aug2002 에 임명되었습니다 의 임기는 22.25 년입니다. 는 CN¥ 3.32B 가치에 해당하는 회사 주식의 25.76% 직접 소유합니다. 3.32B. 경영진과 이사회의 평균 재임 기간은 각각 16.3 년과 4.9 년입니다.

주요 정보

Shao Bo Li

최고 경영자

CN¥326.1k

총 보상

CEO 급여 비율	n/a
CEO 임기	22.3yrs
CEO 소유권	25.8%
경영진 평균 재임 기간	16.3yrs
이사회 평균 재임 기간	4.9yrs

최근 관리 업데이트

Recent updates

CEO

Shao Bo Li (59 yo)

22.3yrs

테뉴어

CN¥326,100

보상

Mr. Shao Bo Li serves as the Chairman and General Manager at Sinocare Inc. since August 07, 2002.

리더십 팀

이름	위치	테뉴어	보상	소유권
Shao Bo Li	Chairman & GM	22.3yrs	CN¥326.10k	25.76% CN¥ 3.3b
Shi Min Wang	Deputy General Manager	16.3yrs	CN¥318.40k	0.14% CN¥ 17.9m
Jianwen Cai	Deputy General Manager	4.1yrs	CN¥2.27m	데이터 없음
Baishen Ouyang	Chairman of the Supervisory Board & Assistant to the GM	no data	데이터 없음	데이터 없음
Chungeng Chen	Supervisor & Supply Chain Director	no data	데이터 없음	데이터 없음

16.3yrs

평균 재임 기간

50yo

평균 연령

경험이 풍부한 관리: 300298 의 관리팀은 노련하고 경험 (평균 재직 기간 16.3 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Shao Bo Li	Chairman & GM	22.3yrs	CN¥326.10k	25.76% CN¥ 3.3b
Baishen Ouyang	Chairman of the Supervisory Board & Assistant to the GM	7.9yrs	데이터 없음	데이터 없음
Chungeng Chen	Supervisor & Supply Chain Director	6.6yrs	데이터 없음	데이터 없음
Hong Yuan	Independent Director	4.9yrs	CN¥120.00k	데이터 없음
Hongjing Che	Non-Independent Director	9.2yrs	CN¥120.00k	0.051% CN¥ 6.6m
Hui Li	Non-Independent Director	4.9yrs	CN¥120.00k	데이터 없음
Xixiong Kang	Independent Director	4.9yrs	CN¥120.00k	데이터 없음
Jizheng Chen	Independent Director	1.9yrs	CN¥120.00k	데이터 없음
Xinyi Li	Vice Chairman	1.9yrs	CN¥565.40k	데이터 없음

4.9yrs

평균 재임 기간

48yo

평균 연령

경험이 풍부한 이사회: 300298 의 이사회는 경험(평균 재직 기간 4.9 년)으로 간주됩니다.

Sinocare 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Sinocare Inc., Annual General Meeting, May 21, 2024

Sinocare Inc. Approves Board Elections

High number of new directors

Sinocare Inc., Annual General Meeting, May 13, 2022

Recent updates

Is Sinocare (SZSE:300298) Using Too Much Debt?

We Think You Can Look Beyond Sinocare's (SZSE:300298) Lackluster Earnings

Consensus EPS estimates fall by 11%

New minor risk - Profit margin trend

Estimating The Intrinsic Value Of Sinocare Inc. (SZSE:300298)

Investor sentiment deteriorates as stock falls 15%

Sinocare (SZSE:300298) Is Reinvesting At Lower Rates Of Return

New minor risk - Share price stability

Sinocare Inc. to Report Q3, 2024 Results on Oct 24, 2024

Now 21% overvalued after recent price rise

Investor sentiment improves as stock rises 15%

Second quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.19 in 2Q 2023)

Sinocare Inc.'s (SZSE:300298) Price Is Out Of Tune With Earnings

Calculating The Intrinsic Value Of Sinocare Inc. (SZSE:300298)

Sinocare Inc. to Report First Half, 2024 Results on Aug 29, 2024

Sinocare Inc. Announces Dividend Implementation for 2023, Payable on 17 June 2024

Is Sinocare (SZSE:300298) A Risky Investment?

Sinocare's (SZSE:300298) Soft Earnings Don't Show The Whole Picture

Price target decreased by 8.0% to CN¥31.01

Sinocare Inc., Annual General Meeting, May 21, 2024

Sinocare Inc. Proposes Final Dividend for 2023

First quarter 2024 earnings released: EPS: CN¥0.15 (vs CN¥0.12 in 1Q 2023)

Investor sentiment improves as stock rises 16%

Sinocare Inc.'s (SZSE:300298) P/E Is On The Mark

Now 21% undervalued after recent price drop

Here's What To Make Of Sinocare's (SZSE:300298) Decelerating Rates Of Return

Sinocare Inc. to Report Q1, 2024 Results on Apr 26, 2024

Now 21% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 16%

Sinocare Inc. to Report Fiscal Year 2023 Results on Apr 26, 2024

Investor sentiment improves as stock rises 24%

Third quarter 2023 earnings released: EPS: CN¥0.26 (vs CN¥0.28 in 3Q 2022)

Now 20% undervalued

Sinocare Inc. to Report Q3, 2023 Results on Oct 24, 2023

Now 20% undervalued after recent price drop

Price target decreased by 14% to CN¥33.71

Second quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.26 in 2Q 2022)

Sinocare Inc. (SZSE:300298) announces an Equity Buyback for CNY 150 million worth of its shares.

Sinocare Inc. (SZSE:300298) announces an Equity Buyback for CNY 150 million worth of its shares.

Now 21% undervalued after recent price drop

Investor sentiment improves as stock rises 17%

Sinocare Inc. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 26 May 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased to CN¥39.34

Sinocare Inc. Approves Board Elections

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.28 (vs CN¥0.14 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.26 (vs CN¥0.13 in 2Q 2021)

Sinocare Inc. Approves Cash Dividend for the Year 2021

Investor sentiment improved over the past week

Consensus forecasts updated

Price target decreased to CN¥20.73

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Sinocare Inc., Annual General Meeting, May 13, 2022

Sinocare Inc. Proposes Cash Dividend for 2021

Third quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.16 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.17 in 2Q 2020)

Price target decreased to CN¥40.66

Consensus forecasts updated

First quarter 2021 earnings released: EPS CN¥0.079 (vs CN¥0.11 in 1Q 2020)

Investor sentiment deteriorated over the past week

New 90-day low: CN¥31.87

Sinocare Inc. to Report Fiscal Year 2020 Results on Apr 17, 2021

New 90-day high: CN¥46.30

Third quarter earnings released

Sinocare Inc. to Report Q3, 2020 Results on Oct 17, 2020

Earnings released

Sinocare Inc. to Report First Half, 2020 Results on Aug 07, 2020

CEO

테뉴어